Short answer
Corvus Pharmaceuticals, Inc. (CRVS) filed an 8-K current report with the SEC on April 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Andrew C. Chan, M.D., Ph.D. appointed Class II director effective April 23, 2026, term expiring at 2027 annual meeting.
Corvus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Andrew C. Chan, M.D., Ph.D. appointed Class II director effective April 23, 2026, term expiring at 2027 annual meeting
- Chan joins Nominating Committee, adding a board seat while replacing departing director Scott Morrison
- Director compensation includes $35,000 annual retainer plus $4,000 Nominating Committee fee
- Initial equity award: option to purchase 30,000 common shares
- Scott Morrison resigns effective April 23, 2026, ending more than a decade of board service and Audit Committee leadership
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Corvus Pharmaceuticals, Inc. 8-K filings
Get the next CRVS 8-K as it lands
Follow CRVS for push alerts, or ask the research agent what this filing means.